Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients.

R P Gray, J S Yudkin, D L Patterson

Department of Medicine, University College and Middlesex School of Medicine, Whittington Hospital, London.

OBJECTIVE--To determine whether diabetic patients admitted with acute myocardial infarction have impaired fibrinolytic activity due to raised plasminogen activator inhibitor compared with non-diabetic patients. SETTING--A district general hospital. PATIENTS--90 non-diabetic and 38 diabetic patients admitted with acute myocardial infarction. RESULTS--Both plasminogen activator inhibitor activity and antigen were significantly higher in diabetic than in non-diabetic patients (24.7 (6.8) v 18.5 (6.8) AU/ml; p = 0.0001 and 64.2 (range 13.1 to 328.8) v 38.5 (range 10.9 to 173.7 ng/ml; z = 3.3; p = 0.0008) with a positive correlation between activity and antigen (rs = 0.51; p = 0.0001). In both groups, activity and antigen concentrations were significantly higher than in diabetic and non-diabetic subjects without coronary artery disease (p = 0.002 to 0.0001 for each comparison). Plasminogen activator inhibitor activity correlated significantly with admission plasma glucose (r = 0.32; p = 0.0001), glycated haemoglobin (r = 0.32; p = 0.0001), admission plasma insulin (rs = 0.48; p = 0.001), and Killip grade of heart failure both on admission (rs = 0.27; p = 0.001) and on discharge (rs = 0.22; p = 0.006), but not with cumulative creatine kinase MB isoenzyme release (rs = -0.08). There were similar but weaker correlations between tissue plasminogen activator antigen and admission plasma glucose, glycated haemoglobin, and insulin. In 18 patients (12 non-diabetic and six diabetic) plasminogen activator inhibitor activity was measured between six and 12 months (8.3 (1.6)) after the acute infarct and remained similar to activity on admission (24.8 (1.9) AU/ml (NS) for diabetic and 17.9 (6.9) AU/ml (NS) for non-diabetic patients) and was still significantly higher in diabetic than in non-diabetic patients (p = 0.007). CONCLUSION--These results show that diabetic patients have higher plasminogen activator inhibitor activity than non-diabetic patients both on admission with acute myocardial infarction and at follow up six to 12 months later. Raised plasminogen activator inhibitor activity may predispose diabetic patients to myocardial infarction and may also impair pharmacological and spontaneous reperfusion after acute myocardial infarction thus contributing to the poor outcome in these subjects.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Hamaguchi, E., Takamura, T., Shimizu, A., Nagai, Y. (2003). Tumor Necrosis Factor-{alpha} and Troglitazone Regulate Plasminogen Activator Inhibitor Type 1 Production through Extracellular Signal-Regulated Kinase- and Nuclear Factor-{kappa}B-Dependent Pathways in Cultured Human Umbilical Vein Endothelial Cells. J. Pharmacol. Exp. Ther. 307: 987-994 [Abstract] [Full Text]  
• Devaraj, S., Chan, A. V. C. Jr., Jialal, I. (2002). {alpha}-Tocopherol Supplementation Decreases Plasminogen Activator Inhibitor-1 and P-Selectin Levels in Type 2 Diabetic Patients. Diabetes Care 25: 524-529 [Abstract] [Full Text]  
• Wahid, S. T., Marshall, S. M., Thomas, T. H. (2001). Increased Platelet and Erythrocyte External Cell Membrane Phosphatidylserine in Type 1 Diabetes and Microalbuminuria. Diabetes Care 24: 2001-2003 [Full Text]  
• Lottermoser, K., Hertfelder, H.-J., Wehling, M., Schiermeyer, B., Vetter, H., Dusing, R. (2000). Effects of the mineralocorticoid fludrocortisone on fibrinolytic function in healthy subjects. Journal of Renin-Angiotensin-Aldosterone System 1: 357-360 [Abstract]  
• Tarnow, L., Stehouwer, C. D. A., Emeis, J. J., Poirier, O., Cambien, F., Hansen, B. V., Parving, H.-H. (2000). Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic angiopathy. Nephrol Dial Transplant 15: 625-630 [Abstract] [Full Text]  
• Killewich, L. A. (2000). Intrinsic Fibrinolysis and Arterial Thrombosis. VASC ENDOVASCULAR SURG 34: 193-199  
• Kajubi, S. K. (2000). Aspirin in the Treatment of Type 2 Diabetes. Arch Intern Med 160: 394-394 [Full Text]  
• Anderson, J. L., Muhlestein, J. B., Habashi, J., Carlquist, J. F., Bair, T. L., Elmer, S. P., Davis, B. P. (1999). Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction. J Am Coll Cardiol 34: 1778-1783 [Abstract] [Full Text]  
• Bouchie, J. L., Hansen, H., Feener, E. P. (1998). Natriuretic Factors and Nitric Oxide Suppress Plasminogen Activator Inhibitor-1 Expression in Vascular Smooth Muscle Cells : Role of cGMP in the Regulation of the Plasminogen System. Arterioscler. Thromb. Vasc. Bio. 18: 1771-1779 [Abstract] [Full Text]  
• Grenett, H. E., Benza, R. L., Fless, G. M., Li, X.-N., Davis, G. C., Booyse, F. M. (1998). Genotype-Specific Transcriptional Regulation of PAI-1 Gene by Insulin, Hypertriglyceridemic VLDL, and Lp(a) in Transfected, Cultured Human Endothelial Cells. Arterioscler. Thromb. Vasc. Bio. 18: 1803-1809 [Abstract] [Full Text]  
• Genser, N., Lechleitner, P., Maier, J., Dienstl, F., Artner-Dworzak, E., Puschendorf, B., Mair, J. (1998). Rebound increase of plasminogen activator inhibitor type 1 after cessation of thrombolytic treatment for acute myocardial infarction is independent of type of plasminogen activator used. Clin. Chem. 44: 209-214 [Abstract] [Full Text]  
• Li, X.-N., Grenett, H. E., Benza, R. L., Demissie, S., Brown, S. L., Tabengwa, E. M., Gianturco, S. H., Bradley, W. A., Fless, G. M., Booyse, F. M. (1997). Genotype-Specific Transcriptional Regulation of PAI-1 Expression by Hypertriglyceridemic VLDL and Lp(a) in Cultured Human Endothelial Cells. Arterioscler. Thromb. Vasc. Bio. 17: 3215-3223 [Abstract] [Full Text]